التفاصيل البيبلوغرافية
| العنوان: |
Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. |
| المؤلفون: |
Østgård, RD, Glerup, H, Jurik, AG, Kragstrup, TW, Stengaard-Pedersen, K, Hetland, ML, Hørslev-Petersen, K, Junker, P, Deleuran, BW |
| المصدر: |
Scandinavian Journal of Rheumatology; Nov2017, Vol. 46 Issue 6, p441-445, 5p |
| مصطلحات موضوعية: |
RHEUMATOID arthritis, HEMOGLOBINS, HEPCIDIN, ERYTHROPOIESIS, FATIGUE (Physiology), PATIENTS, ANTIRHEUMATIC agents, CELL receptors, ENZYME-linked immunosorbent assay, FERRITIN, LONGITUDINAL method, PEPTIDES, BLIND experiment, CASE-control method, BLOOD |
| مستخلص: |
Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA.Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2.Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2-19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9-19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3-9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA.Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA. [ABSTRACT FROM AUTHOR] |
|
Copyright of Scandinavian Journal of Rheumatology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher